Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis b vaccine (recombinant) (GSK, 39d40a)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Engerix-B is a non-infectious recombinant DNA vaccine used to induce active immunity against infection caused by all known subtypes of the hepatitis B virus (HBV). The vaccine contains purified hepatitis B surface antigen (HBsAg), which is produced by genetically engineered yeast cells (*Saccharomyces cerevisiae*) carrying the gene that codes for the surface antigen of HBV. Upon administration, the HBsAg protein stimulates the immune system to produce specific humoral antibodies (anti-HBs), which provide protection against the virus. Engerix-B is indicated for individuals of all ages, including infants, children, and adults. It is particularly utilized in high-risk populations such as healthcare workers, patients with chronic kidney disease (including those on hemodialysis), and patients with diabetes mellitus, who may exhibit diminished immune responses to standard vaccination protocols.
- Brand names
- Engerix-BEngerix B
- Other names
- Hepatitis B Vaccine (Recombinant)HBV vaccineRecombinant Hepatitis B Surface Antigen Vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)T-cell receptor on HBsAg-specific CD4+ T helper cell recognizing HBsAg peptide–MHC class II complexHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis b vaccine (recombinant) (GSK, 39d40a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis b vaccine (recombinant) (GSK, 39d40a).